Literature DB >> 15346243

Predictors of response to therapy for chronic hepatitis C.

Peter Ferenci1.   

Abstract

Pretreatment prediction of successful interferon-based therapy is less accurate than is prediction based on serum hepatitis C virus (HCV) RNA measurements taken during the first few weeks of therapy. Virological response, defined as loss of detectable virus RNA during the first weeks of treatment, identifies interferon-sensitive virus strains. Studies on viral decline kinetics have shown that interferon-based therapies produce a two-phase reduction in viral RNA levels. Sustained virological response is associated with rapid biphasic viral decline kinetics, resulting in elimination of virus from the blood within 4 to 12 weeks. Rapid viral elimination correlates positively with low incidence of relapse in end-of-treatment virological responders and is, therefore, an important parameter for determining duration or type of therapy. This article reviews the various patient and viral factors that help predict response to various interferon-based therapies, ranging from interferon alone to the new pegylated interferons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15346243     DOI: 10.1055/s-2004-832925

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Authors:  M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

2.  Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.

Authors:  D Kmieciak; P Migdalski; J Juszczyk; P P Jagodziński; W H Trzeciak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-28       Impact factor: 3.267

Review 3.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

4.  Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.

Authors:  Vinod K Dixit; Jayanta K Ghosh; Sangey C Lamtha; Pankaj Kaushik; Sundeep K Goyal; Manas K Behera; Neha Singh; Ashok K Jain
Journal:  J Clin Exp Hepatol       Date:  2014-06-18

5.  High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.

Authors:  Marine Karchava; Jesper Waldenström; Monica Parker; Renee Hallack; Lali Sharvadze; Lana Gatserelia; Nikoloz Chkhartishvili; Natia Dvali; Lela Dzigua; Ekaterine Dolmazashvili; Helene Norder; Tengiz Tsertsvadze
Journal:  Hepatol Res       Date:  2015-03-24       Impact factor: 4.288

6.  Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

Authors:  Maria H Sjogren; Robert Sjogren; Michael F Lyons; Michael Ryan; John Santoro; Coleman Smith; K Rajender Reddy; Herbert Bonkovsky; Brooke Huntley; Sima Faris-Young
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 7.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

8.  Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response.

Authors:  Eric Chak; Sammy Saab
Journal:  Curr Hepat Rep       Date:  2010-06-19

9.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

10.  DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.

Authors:  Timothy R Morgan; Richard W Lambrecht; Herbert L Bonkovsky; Raymond T Chung; Deepa Naishadham; Richard K Sterling; Robert J Fontana; William M Lee; Marc G Ghany; Elizabeth C Wright; Thomas R O'Brien
Journal:  J Hepatol       Date:  2008-06-05       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.